By using our site you consent to the CTFN Privacy Policy, Cookies Policy, and Terms of Service.


NxStage/Fresenius Merger: FTC Update

A recommendation to approve a consent order that would allow Fresenius to move forward with its acquisition of NxStage moved from the Federal Trade Commission’s Bureau of Competition to thefeatured

CADE’s General Superintendence to Decide on Fox/Disney by Early Next Week

The General Superintendence of Brazilian antitrust regulator CADE will likely issue its recommendation on the planned merger between 21st Century Fox and the Walt Disney Company early in the week of December 3, a source close to Disney told CTFN.featured

Oregon’s Citizens’ Utility Board Throws a Hail Mary Pass Regarding Avista/Hydro One

Oregon’s utility ratepayer advocate is recommending that state regulators require the Canadian Province of Ontario to pledge in writing that the provincial government will not interfere in the “policies and actions” of Avista Corporationfeatured

Delaware Poised to Approve Genworth Deal

The Delaware Insurance Department appeared ready to clear the acquisition of Genworth Insurance by China Oceanwide Insurance Wednesday when a department official issued a positive recommendation on the $2.7 billion deal.featured

Day 2 of Idaho PUC’s Technical Hearing on Avista/Hydro One Merger

A top executive at Toronto’s Hydro One Ltd. apologized to the Idaho Public Utilities Commission on Tuesday (Nov. 27) after the commission’s president questioned why the company had not alerted the PUCfeatured

From Today’s Idaho PUC Technical Hearing on Avista/Hydro One Merger

Tom Woods, the new board chairman of Toronto-based Hydro One Ltd., told the Idaho Public Utilities Commission November 26 that the company’s largest shareholder—the Canadian Province of Ontario—retains the right to pass legislationfeatured

Strong Demand Likely for Shire/Takeda Divestiture of SHP647

On October 26 Takeda announced it had proposed a remedy to the European Commission of selling Shire’s SHP647, a pipeline compound for the treatment of inflammatory bowel disease, which will potentially compete with Takeda’s marketedfeatured

EC Unlikely to Further Market Test Gemalto/Thales Remedies

The European Commission is unlikely to conduct another market test of the remedies proposed by Thales in connection with its acquisition of Gemalto, a source close to the situationfeatured

Fox/Disney Still Requires China and Brazil Approvals Among Others

Brazil and China are among the main pending hurdles to the closing of the planned merger of Twenty-First Century Fox and Disney.featured

New York DFS Approval Looks in Sight for Aetna/CVS

Communications are ongoing between CVS and the New York Department of Financial Services as the two seek to resolve outstanding issues that would enable DFS tofeatured


Interested in a trial?

Simply fill out the form below and one of our representatives will be in touch.